Esperion Therapeutics | ESPR - Current Liabilities

Stock Price
3.49
Daily Change
0.10 2.80%
Monthly
-1.83%
Yearly
85.37%
Q1 Forecast
2.70

Esperion Therapeutics reported $359.03M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 39.39B 376M Sep/2025
Alnylam Pharmaceuticals USD 1.56B 254.63M Sep/2025
Alterity Therapeutics Limited AUD 4.38M 849.82K Jun/2023
Amarin USD 182.23M 3.71M Sep/2025
Amgen USD 25.49B 3.7B Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Cipla INR 62.97B 8.13B Sep/2025
CSL USD 4.82B 1.26B Jun/2025
Cytokinetics USD 142.14M 11.08M Sep/2025
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Eli Lilly USD 40.14B 1.12B Sep/2025
Esperion Therapeutics USD 359.03M 60.24M Sep/2025
Geron USD 87.71M 23.43M Sep/2025
Grifols EUR 2.53B 182.67M Sep/2025
Halozyme Therapeutics USD 837.23M 702.95M Sep/2025
Heron Therapeutics USD 89.71M 168.89M Sep/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Minerva Neurosciences USD 2.67M 143K Sep/2025
Moderna USD 1.68B 109M Sep/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 866.24M 238.44M Sep/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
United Therapeutics USD 546.3M 19.2M Sep/2025
Vanda Pharmaceuticals USD 117.87M 3.62M Sep/2025